Polaryx Therapeutics, Inc. (NASDAQ:PLYX) Receives Consensus Rating of “Moderate Buy” from Analysts

Polaryx Therapeutics, Inc. (NASDAQ:PLYX) has been assigned a consensus recommendation of “Moderate Buy” from the five analysts that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, two have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $7.6667.

A number of analysts have weighed in on PLYX shares. Wall Street Zen upgraded Polaryx Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Weiss Ratings raised Polaryx Therapeutics from a “sell (e-)” rating to a “sell (e)” rating in a research report on Wednesday, July 1st. Raymond James Financial initiated coverage on Polaryx Therapeutics in a report on Thursday, August 13th. They issued a “strong-buy” rating and a $6.00 price objective on the stock. HC Wainwright initiated coverage on Polaryx Therapeutics in a research report on Thursday, July 9th. They set a “buy” rating and a $7.00 target price on the stock. Finally, Zacks Research upgraded Polaryx Therapeutics to a “hold” rating in a research note on Friday, July 10th.

Polaryx Therapeutics Stock Up 1.0%

NASDAQ PLYX opened at $2.01 on Monday. Polaryx Therapeutics has a 52 week low of $1.85 and a 52 week high of $48.91. The stock has a market capitalization of $100.20 million and a PE ratio of -25.12. The firm has a 50 day moving average of $2.18 and a two-hundred day moving average of $3.44.

Polaryx Therapeutics (NASDAQ:PLYX) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.02. On average, equities research analysts expect that Polaryx Therapeutics will post -0.22 earnings per share for the current fiscal year.

Polaryx Therapeutics Company Profile

We are a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”). Our therapeutic philosophy is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need. Our multi-modal approach integrates small molecule therapies, including a combination therapy, and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs.